...
首页> 外文期刊>Experimental Neurology >Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia.
【24h】

Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia.

机译:可逆性局灶性脑缺血后他莫昔芬对行为和组织的神经保护作用。

获取原文
获取原文并翻译 | 示例
           

摘要

We have previously shown that tamoxifen can reduce infarct sizes measured by 2,3,5,-triphenyltetrazolium chloride (TTC) staining at 72 h after 2 h of reversible middle cerebral artery occlusion (rMCAo) in rats. In this study, we tested whether improvement is found in both behavioral measures of protection and by histological measures of infarcted tissue at 7 and 14 days after 2 h rMCAo. Tamoxifen (10 mg/kg) was given once by intravenous injection 1 h after reperfusion, i.e. 3 h after initiation of rMCAo. Neurobehavioral deficits were evaluated daily for 1 week or 2 weeks followed by infarct volumes measurements by hematoxylin-eosin (HE) staining. Tamoxifen-treated rats had significantly improved neurobehavioral deficit scores when evaluated daily throughout the 1 week or 2 week periods and showed significantly reduced median infarct volumes measured after 1 week and 2 weeks. Median infarct values were 149 mm3 (interquartile range, IQR: 92 to 258) and 124 mm3 (IQR: 69 to 174) for the 1 and 2 week vehicle groups, respectively, compared with 5 mm3 (IQR: 3 to 16) and 4 mm3 (IQR: 0 to 48) for the comparable treated groups (both P < 0.05, Mann-Whitney test), giving a reduction of more than 90% in both cases. Thus, a single administration of tamoxifen given 3 h after initiation of rMCAo is extremely effective in producing long-term neuroprotection as assessed by neurobehavioral measures and histopathology in experimental stroke in rats. If these results are extrapolatable to human stroke, these data indicate that tamoxifen may be a useful neuroprotectant.
机译:先前我们已经表明,他莫昔芬可以减少大鼠可逆性大脑中动脉闭塞(rMCAo)2小时后72小时的2,3,5,-三苯基四唑氯化物(TTC)染色测量的梗塞面积。在这项研究中,我们测试了在2 h rMCAo后第7天和第14天,是否在保护行为措施和梗死组织的组织学措施方面均发现了改善。在再灌注后1小时,即在rMCAo启动后3小时,静脉内注射一次他莫昔芬(10 mg / kg)。每天评估1周或2周的神经行为缺陷,然后通过苏木精-曙红(HE)染色测量梗死体积。用他莫昔芬治疗的大鼠在1周或2周内每天进行评估时,其神经行为缺陷评分显着改善,并且在1周和2周后测得的中位梗死体积显着降低。 1周和2周载具组的中位梗死值分别为149 mm3(四分位间距,IQR:92至258)和124 mm3(IQR:69至174),而5 mm3(IQR:3至16)和4可比较治疗组的mm3(IQR:0至48)(均P <0.05,Mann-Whitney检验),在两种情况下均降低了90%以上。因此,rMCAo启动后3小时给予他莫昔芬单次给药对产生长期神经保护作用极为有效,这是通过大鼠实验性卒中的神经行为学测量和组织病理学评估得出的。如果这些结果可以推断出人类中风,则这些数据表明他莫昔芬可能是有用的神经保护剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号